Breakthrough's Comment On NICE's Draft Decision Not To Recommend Lapatinib (Tyverb) F
 

The National Institute for Health & Clinical Excellence (NICE) have issued a draft decision not to recommend lapatinib (Tyverb) for use on the NHS. A final decision is expected later this year. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This will be disappointing for some women with advanced breast cancer. Breakthrough hopes that if further results from clinical trials are positive this decision will be reviewed in future.

More...